INNV-15. ANALYSIS OF CHALLENGES TO ACCRUAL IN CLINICAL TRIALS FOR NEWLY DIAGNOSED GLIOBLASTOMA. (5th November 2018)

• Record Type: Journal Article
• Authors: Metrus, Nicholas; Daher, Ahmad; Harrison, Rebecca; Majd, Nazanin; Maraka, Stefania; Nam, Joo Yeon; Trevino, Christopher; Weathers, Shiao-Pei; O'Brien, Barbara; Kamiya-Matsuoka, Carlos; Loghin, Monica; Alfaro, Kristin; Hunter, Kathy; Yung, W K Alfred; de Groot, John; Penas-Prado, Marta
• Is Part Of: Neuro-oncology. Volume 20(2018)Supplement 6
• Page Start: vi141
• Page End: vi141
• Publication Date: 2018-11-05
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noy148.588
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: Glioblastoma (GBM) is the most common glioma, with an incidence of 3.2 per 100, 000 adults, and approximately 12, 500 new diagnoses each year in the US. With limited treatment options, there is a constant push to improve patient outcome by testing experimental therapies in clinical trials. However, it is estimated that only 8%-11% of patients with newly diagnosed GBM enroll to clinical trials. METHODS: In an effort to better prioritize patients into appropriate clinical trials and understand barriers to trial enrollment, a weekly Tumor Planning Conference was instituted at MD Anderson Cancer Center in August 2016 to discuss eligibility of each patient with newly diagnosed GBM for available clinical trials. RESULTS: We performed a retrospective review of 112 patients presented over the course of 17 months; data collected included age, gender, date, location and extent of surgery, post-operative day at time of conference, available molecular data and the date(s) it was reported, patients residence and Karnofsky Performance Scale score. A total of 2 to 4 clinical trials for newly diagnosed GBM were available for enrollment at any one time during the analysis. Of the total patients consented for trial participation, 8 were ultimately enrolled and treated into clinical trials (7.14%). The primary reason for no trial participation was study-specific eligibility/ineligibility criteria (such as lack of necessary molecular markers) (46.3%), followed by being out-of-window for trial enrollment (27.4 %). CONCLUSIONS: The weekly tumor planning conference did not improve the number of accruals to trials for newly diagnosed GBM compared to what has been previously reported. However, it provided valuable insights about barriers to trial enrollment, such as the importance of timely outside referrals, efficient new patient scheduling, and need for expedited trial-specific molecular testing.